Payment overview · 2025
General Payments
$174.30
3 reported records · 3 companies
Healthcare provider profile · identity verified
Smitha James Thomas, M.D
Allopathic & Osteopathic Physicians|Family Medicine · CONWAY, AR · NPI 1336245257
Verified facts
What the public records show
CMS Open Payments records show Smitha James Thomas, M.D received $174.30 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 80.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $140.74 | 80.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.39 | 11.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.17 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.30 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $140.74 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 78 |
| Gabapentin | Gabapentin | 320 | 71 |
| Omeprazole | Omeprazole | 287 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 51 |
| Metformin Hcl | Metformin Hcl | 228 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 226 | 39 |
| Atenolol | Atenolol | 207 | 40 |
| Losartan Potassium | Losartan Potassium | 188 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 36 |
| Lisinopril | Lisinopril | 173 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 33 |
| Nifedipine Er | Nifedipine | 166 | 26 |
| Potassium Chloride | Potassium Chloride | 145 | 36 |
| Bupropion Xl | Bupropion Hcl | 144 | 30 |
| Ezetimibe | Ezetimibe | 142 | 26 |
| Meloxicam | Meloxicam | 135 | 34 |
| Furosemide | Furosemide | 131 | 34 |
| Alendronate Sodium | Alendronate Sodium | 130 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 126 | 25 |
| Trazodone Hcl | Trazodone Hcl | 123 | 22 |
| Simvastatin | Simvastatin | 111 | 22 |
| Ozempic | Semaglutide | 110 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 28 |
| Mounjaro | Tirzepatide | 106 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 99 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 17 |
| Sertraline Hcl | Sertraline Hcl | 90 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 21 |
| Carvedilol | Carvedilol | 88 | 17 |
| Allopurinol | Allopurinol | 85 | 14 |
| Montelukast Sodium | Montelukast Sodium | 85 | 17 |
| Jardiance | Empagliflozin | 83 | 14 |
| Folic Acid | Folic Acid | 72 | 12 |
| Buspirone Hcl | Buspirone Hcl | 68 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 12 |
| Baclofen | Baclofen | 62 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Azithromycin | Azithromycin | 47 | 38 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Famotidine | Famotidine | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 11 |
| Pregabalin | Pregabalin | 45 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.30 · 3 records | Abbott Laboratories | ELIQUIS, ESPRIT, General - Vascular Intervention, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error